News coverage about MiMedx Group (NASDAQ:MDXG) has trended somewhat positive recently, according to Accern. Accern identifies negative and positive press coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. MiMedx Group earned a daily sentiment score of 0.23 on Accern’s scale. Accern also gave media headlines about the medical equipment provider an impact score of 44.2754875904715 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
These are some of the media headlines that may have effected Accern Sentiment’s scoring:
A number of equities research analysts have recently weighed in on MDXG shares. BidaskClub raised MiMedx Group from a “hold” rating to a “buy” rating in a report on Wednesday, January 31st. Needham & Company LLC cut MiMedx Group from a “strong-buy” rating to a “hold” rating in a report on Tuesday, February 20th. Lake Street Capital set a $12.00 price target on MiMedx Group and gave the company a “buy” rating in a report on Wednesday, February 21st. Craig Hallum reaffirmed a “buy” rating on shares of MiMedx Group in a report on Tuesday, February 27th. Finally, ValuEngine cut MiMedx Group from a “hold” rating to a “sell” rating in a report on Thursday, March 1st. Four analysts have rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $14.75.
MDXG opened at $7.40 on Friday. The company has a market cap of $821.66 million, a PE ratio of 35.24, a price-to-earnings-growth ratio of 0.96 and a beta of 1.54. MiMedx Group has a twelve month low of $6.05 and a twelve month high of $18.25.
About MiMedx Group
MiMedx Group, Inc, a biopharmaceutical company, develops and markets regenerative biologics utilizing human placental tissue allografts with patent-protected processes for various sectors of healthcare. It processes the human placental tissue utilizing its proprietary PURION Process to produce allografts.
Receive News & Ratings for MiMedx Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiMedx Group and related companies with MarketBeat.com's FREE daily email newsletter.